Soligenix, Inc. (SNGX) is a Biotechnology company in the Healthcare sector, currently trading at $1.15. It has a SharesGrow Score of 32/100, indicating a weak investment profile with 1 out of 7 criteria passed.
Valuation: SNGX trades at a trailing Price-to-Earnings (P/E) of -0.5 (S&P 500 average ~25).
Net income is $11M (loss), growing at -4.5%/yr. Net profit margin is 0% (thin). Gross margin is -104.7% (-146.7 pp trend).
Balance sheet: total debt is $358,144 against $5M equity (Debt-to-Equity (D/E) ratio 0.07, conservative). Current ratio is 2.39 (strong liquidity). Debt-to-assets is 3.9%. Total assets: $9M.
Analyst outlook: 5 / 8 analysts rate SNGX as buy (63%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 0/100 (Fail), Future 55/100 (Partial), Income ?/100 (Fail).
